Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1146/annurev-pharmtox-010716-104558 http://scihub22266oqcxt.onion/10.1146/annurev-pharmtox-010716-104558 C6035745!6035745 !28061688     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=28061688 &cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215       Annu+Rev+Pharmacol+Toxicol 2017 ; 57 (?): 61-79 Nephropedia Template TP {{tp|p=28061688 |t=2017. Aptamers as Therapeutics |pdf=|usr=}}{{28061688 }} gab.com Text Aptamers as Therapeutics JO: Annu Rev Pharmacol Toxicol http://www.kidney.de/pget.php?&tw=1&pmid=28061688 #FOAvip Aptamers are single-stranded nucleic acid molecules that bind to and inhibit proteins and are commonly produced by systematic evolution of ligands by exponential enrichment (SELEX). Aptamers undergo extensive pharmacological revision, which alters affinity, specificity, and therapeutic half-life, tailoring each drug for a specific clinical need. The first therapeutic aptamer was described 25 years ago. Thus far, one aptamer has been approved for clinical use, and numerous others are in preclinical or clinical development. This review presents a short history of aptamers and SELEX, describes their pharmacological development and optimization, and reviews potential treatment of diseases including visual disorders, thrombosis, and cancer. Twit Text FOAVip Aptamers as Therapeutics ????Annu Rev Pharmacol Toxicol http://www.kidney.de/pget.php?&tw=1&pmid=28061688 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=28061688 #FOAvip English Wikipedia <ref>{{Cite pmid|28061688 }}</ref> Aptamers as Therapeutics #MMPMID28061688 Nimjee SM ; White RR ; Becker RC ; Sullenger BA Annu Rev Pharmacol Toxicol 2017[Jan]; 57 (?): 61-79 PMID28061688 show ga Aptamers are single-stranded nucleic acid molecules that bind to and inhibit proteins and are commonly produced by systematic evolution of ligands by exponential enrichment (SELEX). Aptamers undergo extensive pharmacological revision, which alters affinity, specificity, and therapeutic half-life, tailoring each drug for a specific clinical need. The first therapeutic aptamer was described 25 years ago. Thus far, one aptamer has been approved for clinical use, and numerous others are in preclinical or clinical development. This review presents a short history of aptamers and SELEX, describes their pharmacological development and optimization, and reviews potential treatment of diseases including visual disorders, thrombosis, and cancer. |Animals [MESH] |Aptamers, Nucleotide/*administration & dosage/*genetics/metabolism [MESH] |Humans [MESH] |Neoplasms/drug therapy/metabolism [MESH] |Randomized Controlled Trials as Topic/methods [MESH] |SELEX Aptamer Technique/*methods/trends [MESH]Aptamers as Therapeutics (epmc).pdf DeepDyve Pubget Overpricing